Is GW0742 legal in the United Kingdom?

The sibling of GW501516, sold on the same endurance story with none of the same evidence. No human study of GW0742 of any design has ever been published, and the endurance result is mice on a treadmill.

GW0742 is a selective agonist at PPAR-beta/delta, the same nuclear receptor GW501516 targets, from the same GlaxoSmithKline chemistry. It is sold in the research chemical market as the newer, cleaner cardarine.

Mechanism: Selective agonism at PPAR-beta/delta, a nuclear receptor that upregulates fatty acid oxidation and mitochondrial genes in skeletal muscle. In the mouse combination study, GW0742-treated groups tended to higher PGC-1alpha protein, and at exhaustion Pgc1a, Pdk4, Cd36 and Lpl were upregulated in muscle, with a measurable shift from carbohydrate to fat as the fuel and glycogen sparing that delayed hypoglycaemia.

Regulatory history: Never approved and never tested in a registered human trial. Prohibited in sport by WADA alongside the rest of the PPAR-delta agonist class.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for GW0742 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.